Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • CCC Cancer Update
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Breast cancer research : BCR. 2016 Feb 9. doi: 10.1186/s13058-016-0671-y. pii: 10.1186/s13058-016-0671-y
    Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
    Silvestri V1,  Barrowdale D2,  Mulligan AM3,  Neuhausen SL4,  Fox S5,  Karlan BY6,  Mitchell G7,  James P8,  Thull DL9,  Zorn KK10,  Carter NJ11,  Nathanson KL12,  Domchek SM13,  Rebbeck TR14,  Ramus SJ15,  Nussbaum RL16,  Olopade OI17,  Rantala J18,  Yoon SY19,  Caligo MA20,  Spugnesi L21,  Bojesen A22,  Pedersen IS23,  Thomassen M24,  Jensen UB25,  Toland AE26,  Senter L27,  Andrulis IL28,  Glendon G29,  Hulick PJ30,  Imyanitov EN31,  Greene MH32,  Mai PL33,  Singer CF34,  Rappaport-Fuerhauser C35,  Kramer G36,  Vijai J37,  Offit K38,  Robson M39,  Lincoln A40,  Jacobs L41,  Machackova E42,  Foretova L43,  Navratilova M44,  Vasickova P45,  Couch FJ46,  Hallberg E47,  Ruddy KJ48,  Sharma P49,  Kim SW50,  Teixeira MR51,  Pinto P52,  Montagna M53,  Matricardi L54,  Arason A55,  Johannsson OT56,  Barkardottir RB57,  Jakubowska A58,  Lubinski J59,  Izquierdo A60,  Pujana MA61,  Balmaña J62,  Diez O63,  Ivady G64,  Papp J65,  Olah E66,  Kwong A67,  Nevanlinna H68,  Aittomäki K69,  Perez Segura P70,  Caldes T71,  Van Maerken T72,  Poppe B73,  Claes KB74,  Isaacs C75,  Elan C76,  Lasset C77,  Stoppa-Lyonnet D78,  Barjhoux L79,  Belotti M80,  Meindl A81,  Gehrig A82,  Sutter C83,  Engel C84,  Niederacher D85,  Steinemann D86,  Hahnen E87,  Kast K88,  Arnold N89,  Varon-Mateeva R90,  Wand D91,  Godwin AK92,  Evans DG93,  Frost D94,  Perkins J95,  Adlard J96,  Izatt L97,  Platte R98,  Eeles R99,  Ellis S100,  Hamann U101,  Garber J102,  Fostira F103,  Fountzilas G104,  Pasini B105,  Giannini G106,  Rizzolo P107,  Russo A108,  Cortesi L109,  Papi L110,  Varesco L111,  Palli D112,  Zanna I113,  Savarese A114,  Radice P115,  Manoukian S116,  Peissel B117,  Barile M118,  Bonanni B119,  Viel A120,  Pensotti V121,  Tommasi S122,  Peterlongo P123,  Weitzel JN124,  Osorio A125,  Benitez J126,  McGuffog L127,  Healey S128,  Gerdes AM129,  Ejlertsen B130,  Hansen TV131,  Steele L132,  Ding YC133,  Tung N134,  Janavicius R135,  Goldgar DE136,  Buys SS137,  Daly MB138,  Bane A139,  Terry MB140,  John EM141,  Southey M142,  Easton DF143,  Chenevix-Trench G144,  Antoniou AC145,  Ottini L146
    Author information
    1Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy. valentina.silvestri@uniroma1.it.
    2Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. daniel@srl.cam.ac.uk.
    3Laboratory Medicine Program, University Health Network, Toronto, ON, Canada. annamarie.mulligan@uhn.ca.
    4Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. sneuhausen@coh.org.
    5Peter MacCallum Cancer Institute, East Melbourne, Australia. stephen.fox@petermac.org.
    6Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. beth.karlan@cshs.org.
    7Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Australia. gillian.mitchell@petermac.org.
    8Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Australia. paul.james@petermac.org.
    9University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. dthull@magee.edu.
    10University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. kkzorn@uams.edu.
    11UPMC Cancer Center, Pittsburgh, PA, USA. engeln@upmc.edu.
    12Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA. knathans@exchange.upenn.edu.
    13Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA. susan.domchek@uphs.upenn.edu.
    14Department of Epidemiology and Biostatistics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. rebbeck@exchange.upenn.edu.
    15Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA. sramus@usc.edu.
    16Department of Medicine and Genetics, University of California, San Francisco, San Francisco, CA, USA. nussbaumr@humgen.ucsf.edu.
    17Center for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Chicago, IL, USA. folopade@medicine.bsd.uchicago.edu.
    18Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. johanna.rantala@karolinska.se.
    19Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Malaysia. sookyee.yoon@carif.com.my.
    20Section of Genetic Oncology, Department of Laboratory Medicine, University of Pisa and University Hospital of Pisa, Pisa, Italy. adelaide.caligo@do.unipi.it.
    21Section of Genetic Oncology, Department of Laboratory Medicine, University of Pisa and University Hospital of Pisa, Pisa, Italy. laura.spugnesi@gmail.com.
    22Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark. anders.bojesen@slb.regionsyddanmark.dk.
    23Section of Molecular Diagnostics, Department of Biochemistry, Aalborg University Hospital, Aalborg, Denmark. isp@rn.dk.
    24Department of Clinical Genetics, Odense University Hospital, Odense C, Denmark. mads.thomassen@rsyd.dk.
    25Department of Clinical Genetics, Aarhus University Hospital, Aarhus N, Denmark. uffejens@rm.dk.
    26Department of Molecular Virology, Immunology and Medical Genetics, College of Medicine, The Ohio State University, Columbus, OH, USA. amanda.toland@osumc.edu.
    27Division of Human Genetics, Department of Internal Medicine, The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. leigha.senter@osumc.edu.
    28Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. andrulis@lunenfeld.ca.
    29Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada. gord.glendon@cancercare.on.ca.
    30Center for Medical Genetics, North Shore University Health System, Evanston, IL, USA. phulick@northshore.org.
    31N.N. Petrov Institute of Oncology, St. Petersburg, Russia. evgeny@imyanitov.spb.ru.
    32Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. greenem@mail.nih.gov.
    33Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. maip@mail.nih.gov.
    34Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. christian.singer@meduniwien.ac.at.
    35Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. christine.rappaport@akhwien.at.
    36Department of Urology, Medical University of Vienna, Vienna, Austria. gero.kramer@meduniwien.ac.at.
    37Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. josephv@mskcc.org.
    38Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. offitk@mskcc.org.
    39Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. robsonm@mskcc.org.
    40Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. lincolna@mskcc.org.
    41Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. jacobsl@mskcc.org.
    42Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic. emachack@mou.cz.
    43Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic. foretova@mou.cz.
    44Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic. mnavrati@mou.cz.
    45Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic. vasickova@mou.cz.
    46Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. couch.fergus@mayo.edu.
    47Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. hallberg.emily@mayo.edu.
    48Department of Oncology, Mayo Clinic, Rochester, MN, USA. ruddy.kathryn@mayo.edu.
    49Department of Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS, USA. psharma2@kumc.edu.
    50Department of Surgery, Daerim St. Mary's Hospital, Seoul, Korea. brcakorea@gmail.com.
    51Department of Genetics, Portuguese Institute of Oncology, Porto, Portugal. manuel.teixeira@ipoporto.min-saude.pt.
    52Department of Genetics, Portuguese Institute of Oncology, Porto, Portugal. pedro.pinto@ipoporto.min-saude.pt.
    53Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS (Scientific Institute of Hospitalization and Care), Padua, Italy. montagna@unipd.it.
    54Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS (Scientific Institute of Hospitalization and Care), Padua, Italy. laura.matricardi@ioveneto.it.
    55Department of Pathology, Landspitali University Hospital and Biomedical Centre (BMC), Faculty of Medicine, University of Iceland, Reykjavik, Iceland. adalgeir@landspitali.is.
    56Department of Oncology, Landspitali University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland. oskarjoh@landspitali.is.
    57Department of Pathology, Landspitali University Hospital and Biomedical Centre (BMC), Faculty of Medicine, University of Iceland, Reykjavik, Iceland. rosa@landspitali.is.
    58Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. aniaj@pum.edu.pl.
    59Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. lubinski@pum.edu.pl.
    60Genetic Counseling Unit, Hereditary Cancer Program, Biomedical Research Institute of Girona (IDIBGI), Catalan Institute of Oncology, Girona, Spain. aizquierdo@iconcologia.net.
    61Breast Cancer and Systems Biology Unit, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Barcelona, Spain. mapujana@iconcologia.net.
    62Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. jbalmana@vhebron.net.
    63Oncogenetics Group, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) and Universitat Autònoma de Barcelona, Barcelona, Spain. odiez@vhebron.net.
    64Department of Pathology, National Institute of Oncology, Budapest, Hungary. ivadygabi@oncol.hu.
    65Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary. janos.papp@oncol.hu.
    66Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary. e.olah@oncol.hu.
    67The Hong Kong Hereditary Breast Cancer Family Registry, Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong, China. akwong@asiabreastregistry.com.
    68Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. heli.nevanlinna@hus.fi.
    69Department of Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. kristiina.aittomaki@hus.fi.
    70Department of Oncology, San Carlos Clinical Hospital Health Research Institute (IdISSC), San Carlos Clinical Hospital, Madrid, Spain. pperez.hcsc@salud.madrid.org.
    71Molecular Oncology Laboratory, San Carlos Clinical Hospital Health Research Institute (IdISSC), San Carlos Clinical Hospital, Madrid, Spain. trinidad.caldes@salud.madrid.org.
    72Center for Medical Genetics, Ghent University, Ghent, Belgium. tom.vanmaerken@ugent.be.
    73Center for Medical Genetics, Ghent University, Ghent, Belgium. bruce.poppe@ugent.be.
    74Center for Medical Genetics, Ghent University, Ghent, Belgium. Kathleen.Claes@UGent.be.
    75Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. isaacsc@georgetown.edu.
    76Department of Tumour Biology, Institut Curie, Paris, France. camille.elan@curie.net.
    77CNRS UMR5558, Université Lyon 1, Lyon, France. christine.lasset@lyon.unicancer.fr.
    78Department of Tumour Biology, Institut Curie, Paris, France. dominique.stoppa-lyonnet@curie.net.
    79INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université Lyon, Lyon, France. laure.barjhoux@lyon.unicancer.fr.
    80Department of Tumour Biology, Institut Curie, Paris, France. muriel.belotti@curie.net.
    81Department of Gynaecology and Obstetrics, Technical University of Munich, Munich, Germany. alfons.meindl@lrz.tu-muenchen.de.
    82Institute of Human Genetics, University of Wurzburg, Wurzburg, Germany. gehrig@biozentrum.uni-wuerzburg.de.
    83Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany. c.sutter@med.uni-heidelberg.de.
    84Institute for Medical Informatics, Statistics and Epidemiology University of Leipzig, Leipzig, Germany. christoph.engel@imise.uni-leipzig.de.
    85University of Dusseldorf, Dusseldorf, Germany. niederac@uni-duesseldorf.de.
    86Hannover Medical School, Hannover, Germany. steinemann.doris@mh-hannover.de.
    87Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany. eric.hahnen@uk-koeln.de.
    88Department of Gynecology and Obstetrics, Technical University of Dresden, Dresden, Germany. karin.kast@uniklinikum-dresden.de.
    89Department of Gynaecolgy and Obstetrics, University Hospital of Schleswig-Holstein, Christian-Albrechts-University of Kiel, Kiel, Germany. norbert.arnold@uksh.de.
    90Institute of Human Genetics, Charité, Berlin, Germany. raymonda.varon-mateeva@charite.de.
    91Institute of Human Genetics, Leipzig, Germany. dorothea.wand@medizin.uni-leipzig.de.
    92Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA. agodwin@kumc.edu.
    93Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. gareth.evans@cmft.nhs.uk.
    94Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. djsf2@medschl.cam.ac.uk.
    95Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. jp410@medschl.cam.ac.uk.
    96Yorkshire Regional Genetics Service, Leeds, UK. julian.adlard@leedsth.nhs.uk.
    97Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, London, UK. louise.izatt@gstt.nhs.uk.
    98Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK. rp356@medschl.cam.ac.uk.
    99Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. rosalind.eeles@icr.ac.uk.
    100Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. steve@srl.cam.ac.uk.
    101Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. u.hamann@dkfz-heidelberg.de.
    102Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, MA, USA. judy_garber@dfci.harvard.edu.
    103Molecular Diagnostics Laboratory, Institute of Nuclear and Radiological Sciences and Technology (INRASTES), National Centre for Scientific Research "Demokritos", Aghia Paraskevi Attikis, Athens, Greece. florentia@rrp.demokritos.gr.
    104Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece. fountzil@auth.gr.
    105Department of Medical Science, University of Turin, Turin, Italy. barbara.pasini@unito.it.
    106Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy. giuseppe.giannini@uniroma1.it.
    107Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy. piera.rizzolo@uniroma1.it.
    108Section of Medical Oncology, Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy. lab-oncobiologia@usa.net.
    109Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy. hbc@unimore.it.
    110Unit of Medical Genetics, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy. laura.papi@unifi.it.
    111Unit of Hereditary Cancer, Department of Epidemiology, Prevention and Special Functions, IRCCS (Scientific Institute of Hospitalization and Care), AOU San Martino - IST National Institute for Cancer Research, Genoa, Italy. liliana.varesco@hsanmartino.it.
    112Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy. d.palli@ispo.toscana.it.
    113Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy. i.zanna@ispo.toscana.it.
    114Unit of Genetic Counselling, Medical Oncology Department, Regina Elena National Cancer Institute, Rome, Italy. savarese@ifo.it.
    115Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, IRCCS (Scientific Institute of Hospitalization and Care), National Cancer Institute (INT), 20133, Milan, Italy. paolo.radice@istitutotumori.mi.it.
    116Unit of Medical Genetics, Department of Preventive and Predictive Medicine, IRCCS (Scientific Institute of Hospitalization and Care), National Cancer Institute (INT), Milan, Italy. siranoush.manoukian@istitutotumori.mi.it.
    117Unit of Medical Genetics, Department of Preventive and Predictive Medicine, IRCCS (Scientific Institute of Hospitalization and Care), National Cancer Institute (INT), Milan, Italy. bernard.peissel@istitutotumori.mi.it.
    118Division of Cancer Prevention and Genetics, European Institute of Oncology (IEO), Milan, Italy. monica.barile@ieo.it.
    119Division of Cancer Prevention and Genetics, European Institute of Oncology (IEO), Milan, Italy. bernardo.bonanni@ieo.it.
    120Division of Experimental Oncology, CRO Aviano National Cancer Institute, Aviano, PN, Italy. aviel@cro.it.
    121IFOM, FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy. valeria.pensotti@ifom.eu.
    122National Cancer Institute "Giovanni Paolo II", Bari, Italy. s.tommasi@oncologico.bari.it.
    123IFOM, FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy. paolo.peterlongo@ifom.eu.
    124Clinical Cancer Genetics, City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA. jweitzel@coh.org.
    125Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Centre (CNIO), Madrid, Spain. aosorio@cnio.es.
    126Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain. jbenitez@cnio.es.
    127Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. lesley@srl.cam.ac.uk.
    128Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Australia. sue.healey@qimrberghofer.edu.au.
    129Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. anne-marie.gerdes@regionh.dk.
    130Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. bent.ejlertsen@regionh.dk.
    131Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. tvoh@rh.dk.
    132Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. lsteele@coh.org.
    133Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. ycding@coh.org.
    134Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA. ntung@bidmc.harvard.edu.
    135State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania. ramunas.janavicius@santa.lt.
    136Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. david.goldgar@hsc.utah.edu.
    137Department of Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. saundra.buys@hci.utah.edu.
    138Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA. mary.daly@fccc.edu.
    139Department of Pathology & Molecular Medicine, Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada. bane@hhsc.ca.
    140Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. mt146@cumc.columbia.edu.
    141Department of Epidemiology, Cancer Prevention Institute of California, Fremont, CA, USA. esther.john@cpic.org.
    142Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Parkville, Australia. msouthey@unimelb.edu.au.
    143Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. douglas@srl.cam.ac.uk.
    144Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Australia. georgia.trench@qimrberghofer.edu.au.
    145Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK. antonis@srl.cam.ac.uk.
    146Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, 324, 00161, Rome, Italy. laura.ottini@uniroma1.it.
    Abstract

    BACKGROUND: BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).

    METHODS: We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database.

    RESULTS: Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10(-5)) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80] and progesterone receptor-positive (OR 5.04; 95 % CI 3.17-8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10(-12)).

    CONCLUSIONS: On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.


    Publikations ID: 26857456
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt